University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Surgery (Austin & Northern Health)
  • Surgery (Austin & Northern Health) - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Surgery (Austin & Northern Health)
  • Surgery (Austin & Northern Health) - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

    Thumbnail
    Download
    Published version (736.0Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    59
    46
    Author
    Chia, PL; Mitchell, P; Dobrovic, A; John, T
    Date
    2014-01-01
    Source Title
    Clinical Epidemiology
    Publisher
    DOVE MEDICAL PRESS LTD
    University of Melbourne Author/s
    Mitchell, Paul; Dobrovic, Alexander; Chia, Puey Ling
    Affiliation
    Surgery (Austin & Northern Health)
    Medicine and Radiology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Chia, P. L., Mitchell, P., Dobrovic, A. & John, T. (2014). Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. CLINICAL EPIDEMIOLOGY, 6, pp.423-432. https://doi.org/10.2147/CLEP.S69718.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/258190
    DOI
    10.2147/CLEP.S69718
    Abstract
    Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Medicine and Radiology - Research Publications [2347]
    • Surgery (Austin & Northern Health) - Research Publications [277]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors